{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:13:08Z","timestamp":1790863988905,"version":"4.1.0"},"reference-count":40,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Prescribing cascades contribute to the increasing prevalence of polypharmacy and its associated risks, where a drug-induced adverse event is misinterpreted as a new condition and treated with additional medications. Notable cascades include the use of anticholinergics leading to cognitive impairment, dyspepsia or constipation, which then prompt prescriptions for dementia medications, proton pump inhibitors or laxatives, respectively. Similarly, calcium channel blockers and gabapentinoids often induce oedema, resulting in unnecessary diuretic use. Strategies for prevention include careful review of adverse effects, deprescribing where appropriate and clinician education to improve symptom interpretation and prescribing practices. Recognising these cascades can mitigate unnecessary interventions and improve patient outcomes.<\/jats:p>","DOI":"10.4102\/phcfm.v17i1.4929","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:03:25Z","timestamp":1743451405000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reducing prescribing cascades"],"prefix":"10.4102","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5496-1470","authenticated-orcid":false,"given":"Aaron M.","family":"Tejani","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-4206","authenticated-orcid":false,"given":"Thomas L.","family":"Perry","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rmrcq20","id-type":"ROR","asserted-by":"publisher"}],"name":"University of British Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Lee GB, Etherton-Beer C, Hosking SM, et al. The patterns and implications of potentially suboptimal medicine regimens among older adults: A narrative review. Therap Adv Drug Saf. 2022;13:20420986221100117. https:\/\/doi.org\/10.1177\/20420986221100117","DOI":"10.1177\/20420986221100117"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Rochon PA, Gurwitz JH. Drug therapy. Lancet. 1995;346(8966):32\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(95)92656-9","DOI":"10.1016\/S0140-6736(95)92656-9"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017; 389(10081):1778\u20131780. https:\/\/doi.org\/10.1016\/S0140-6736(17)31188-1","DOI":"10.1016\/S0140-6736(17)31188-1"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chen Z, Liu Z, Zeng L, Huang L, Zhang L. Research on prescribing cascades: A scoping review. Front Pharmacol. 2023;14:1147921. https:\/\/doi.org\/10.3389\/fphar.2023.1147921","DOI":"10.3389\/fphar.2023.1147921"},{"key":"ref4","unstructured":"Ravinandan AP, Eswaran M. Study on knowledge, attitude, and perception (KAP) of nursing students on adverse drug reaction due to prescribing cascade among elderly patients in Tumkur. Afr J Biol Sci [serial online]. 2024 [cited 2025 Feb 07];6(6):1352\u20131363. Available from: https:\/\/www.afjbs.com\/uploads\/paper\/6ecba9594dc5f841e6e563d35617ffa5.pdf"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"McCarthy LM, Savage R, Dalton K, et al. ThinkCascades: A tool for identifying clinically important prescribing cascades affecting older people. Drugs Aging. 2022;39(10):829\u2013840. https:\/\/doi.org\/10.1007\/s40266-022-00964-9","DOI":"10.1007\/s40266-022-00964-9"},{"key":"ref6","unstructured":"Therapeutics Initiative. How well do you know your anticholinergic (antimuscarinic) drugs? Therap Lett [serial online]. 2018 [cited 2025 Feb 10];113. Available from: https:\/\/ti.ubc.ca\/letter113"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer Disease. Am J Geriatr Psychiatry. 2003;11(4):458\u2013461. https:\/\/doi.org\/10.1097\/00019442-200307000-00009","DOI":"10.1097\/00019442-200307000-00009"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Taylor-Rowan M, Edwards S, Noel-Storr AH, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5:CD013540. https:\/\/doi.org\/10.1002\/14651858.CD013540.pub2","DOI":"10.1002\/14651858.CD013540.pub2"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kurata K, Taniai E, Nishimura K, et al. A prescription survey about combined use of acetylcholinesterase inhibitors and anticholinergic medicines in the dementia outpatient using electronic medication history data from community pharmacies. Integr Pharm Res Pract. 2015;4:133\u2013141. https:\/\/doi.org\/10.2147\/IPRP.S86661","DOI":"10.2147\/IPRP.S86661"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808\u2013813. https:\/\/doi.org\/10.1001\/archinte.165.7.808","DOI":"10.1001\/archinte.165.7.808"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Trenaman SC, Bowles SK, Kirkland S, Andrew MK. An examination of three prescribing cascades in a cohort of older adults with dementia. BMC Geriatr. 2021;21(1):297. https:\/\/doi.org\/10.1186\/s12877-021-02246-2","DOI":"10.1186\/s12877-021-02246-2"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med. 2009;169(9):867\u2013873. https:\/\/doi.org\/10.1001\/archinternmed.2009.43","DOI":"10.1001\/archinternmed.2009.43"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Ruangritchankul S, Chantharit P, Srisuma S, Gray LC. Adverse drug reactions of acetylcholinesterase inhibitors in older people Living with dementia: A comprehensive literature review. Ther Clin Risk Manage. 2021;17:927\u2013949. https:\/\/doi.org\/10.2147\/TCRM.S323387","DOI":"10.2147\/TCRM.S323387"},{"key":"ref14","unstructured":"Pfizer Canada. Aricept (donepezil hydrochloride) product monograph, revised Dec. 18 [homepage on the Internet]. 2014 [cited 2025 Feb 10]. Available from: https:\/\/www.pfizer.ca\/sites\/default\/files\/201612\/ARICEPT_PM_E_177353_18Dec2014_R.pdf"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mangin D, Lawson J, Cuppage J, et al. Legacy drug-prescribing patterns in primary care. Ann Fam Med. 2018;16(6):515\u2013520. https:\/\/doi.org\/10.1370\/afm.2315","DOI":"10.1370\/afm.2315"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Rababa M, Al-Ghassani AA, Kovach CR, Dyer EM. Proton pump inhibitors and the prescribing cascade. J Gerontol Nurs. 2016;42(4):23\u201331. https:\/\/doi.org\/10.3928\/00989134-20151218-04","DOI":"10.3928\/00989134-20151218-04"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Trenaman SC, Harding A, Bowles SK, et al. A prescribing cascade of proton pump inhibitors following anticholinergic medications in older adults with dementia. Front Pharmacol. 2022;13:878092. https:\/\/doi.org\/10.3389\/fphar.2022.878092","DOI":"10.3389\/fphar.2022.878092"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rodriguez-Ramallo H, Baez-Gutierrez N, Prado-Mel E, et al. Association between anticholinergic burden and constipation: A systematic review. Healthcare. 2021;9(5):581. https:\/\/doi.org\/10.3390\/healthcare9050581","DOI":"10.3390\/healthcare9050581"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Elli C, Novella A, Nobili A, et al. Laxative agents in nursing homes: An example of prescribing cascade. J Am Med Directors Assoc. 2021;22(12):2559\u20132564. https:\/\/doi.org\/10.1016\/j.jamda.2021.04.021","DOI":"10.1016\/j.jamda.2021.04.021"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: Incidence and withdrawal rate \u2013 A meta-analysis of randomized trials. J Hyperten. 2011;29(7):1270\u20131280. https:\/\/doi.org\/10.1097\/HJH.0b013e3283472643","DOI":"10.1097\/HJH.0b013e3283472643"},{"key":"ref21","unstructured":"AstraZeneca Canada. Plendil (felodipine) product monograph, revised Jan. 15 [homepage on the Internet]. 2015. Available from: https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/plendil-product-monograph-en.pdf"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020;180(5):643\u2013651. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7087","DOI":"10.1001\/jamainternmed.2019.7087"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Vouri SM, Jiang X, Manini TM, et al. Magnitude of and characteristics associated with the treatment of calcium channel blocker\u2013induced lower-extremity edema with loop diuretics. JAMA Network Open. 2019;2(12):e1918425. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18425","DOI":"10.1001\/jamanetworkopen.2019.18425"},{"key":"ref24","unstructured":"Therapeutics Initiative. Gabapentin for pain: New evidence from hidden data. Therap Lett [serial online]. 2009 [cited 2025 Feb 10];75. Available from: https:\/\/ti.ubc.ca\/letter75"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Falk J, Thomas B, Kirkwood J, et al. PEER systematic review of randomized controlled trials. Management of chronic neuropathic pain in primary care. Can Fam Physician. 2021;67(5):e130\u2013e140. https:\/\/doi.org\/10.46747\/cfp.6705e130","DOI":"10.46747\/cfp.6705e130"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: A systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52(4):826\u2013836. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02966.x","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Read SH, Giannakeas V, Pop P, et al. Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain. J Am Geriatr Soc. 2021;69(10):2842\u20132850. https:\/\/doi.org\/10.1111\/jgs.17312","DOI":"10.1111\/jgs.17312"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Ho JM, Macdonald EM, Luo J, et al. Pregabalin and heart failure: A population-based study. Pharmacoepidemiol Drug Safety. 2017;26(9):1087\u20131092. https:\/\/doi.org\/10.1002\/pds.4239","DOI":"10.1002\/pds.4239"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882\u20131888. https:\/\/doi.org\/10.1001\/archinte.165.16.1882","DOI":"10.1001\/archinte.165.16.1882"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: A case-control study. Am J Med. 1995;99(1):48\u201354. https:\/\/doi.org\/10.1016\/S0002-9343(99)80104-1","DOI":"10.1016\/S0002-9343(99)80104-1"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Tsai SC, Sheu SY, Chien LN, et al. High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: A nationwide population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2000\u20132009. https:\/\/doi.org\/10.1111\/bcp.13630","DOI":"10.1111\/bcp.13630"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Avorn J, Gurwitz JH, Bohn RL, et al. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995;274(22):1780\u20131782. https:\/\/doi.org\/10.1001\/jama.1995.03530220046031","DOI":"10.1001\/jama.1995.03530220046031"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Huh Y, Kim DH, Choi M, et al. Metoclopramide and levosulpiride use and subsequent levodopa prescription in the Korean elderly: The prescribing cascade. J Clin Med. 2019;8(9):1496. https:\/\/doi.org\/10.3390\/jcm8091496","DOI":"10.3390\/jcm8091496"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Vitarello JA, Fitzgerald CJ, Cluett JL, et al. Prevalence of medications that may raise blood pressure among adults with hypertension in the United States. JAMA Intern Med. 2022;182(1):90\u201393. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6819","DOI":"10.1001\/jamainternmed.2021.6819"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Brath H, Mehta N, Savage RD, et al. What is known about preventing, detecting, and reversing prescribing cascades: A scoping review. J Am Geriatr Soc. 2018;66(11):2079\u20132085. https:\/\/doi.org\/10.1111\/jgs.15543","DOI":"10.1111\/jgs.15543"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Farrell B, Galley E, Jeffs L, et al. \u201cKind of blurry\u201d: Deciphering clues to prevent, investigate and manage prescribing cascades. PLoS One. 2022;17(8):e0272418. https:\/\/doi.org\/10.1371\/journal.pone.0272418","DOI":"10.1371\/journal.pone.0272418"},{"key":"ref37","unstructured":"Gagnon C, Currie J, Trimble J. Are you the victim of a prescribing cascade? [homepage on the Internet] Canadian Deprescribing Network; 2020 [cited 2025 Feb 10]. Available from: https:\/\/www.deprescribingnetwork.ca\/blog\/prescribing-cascade"},{"key":"ref38","unstructured":"Therapeutics Initiative. Reducing polypharmacy: A logical approach. Therap Lett [serial online]. 2014 [cited 2025 Feb 10];90. Available from: https:\/\/ti.ubc.ca\/letter90"},{"key":"ref39","unstructured":"Therapeutics Initiative. Reducing prescribing cascades. Therap Lett [serial online]. 2022 [cited 2025 Feb 10];138. Available from: https:\/\/www.ti.ubc.ca\/letter138"}],"container-title":["African Journal of Primary Health Care &amp; Family Medicine"],"original-title":[],"link":[{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4929\/8085","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4929\/8086","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4929\/8087","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/viewFile\/4929\/8088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4929\/8088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:33:12Z","timestamp":1762335192000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/4929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/phcfm.v17i1.4929","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"article-number":"a4929"}}